CBT124 + EU-sourced Avastin® + Carboplatin + Paclitaxel
Phase 3UNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Small Cell Lung Carcinoma
Conditions
Non-Small Cell Lung Carcinoma
Trial Timeline
Dec 1, 2016 → May 1, 2018
NCT ID
NCT02879097About CBT124 + EU-sourced Avastin® + Carboplatin + Paclitaxel
CBT124 + EU-sourced Avastin® + Carboplatin + Paclitaxel is a phase 3 stage product being developed by Cipla for Non-Small Cell Lung Carcinoma. The current trial status is unknown. This product is registered under clinical trial identifier NCT02879097. Target conditions include Non-Small Cell Lung Carcinoma.
What happened to similar drugs?
20 of 20 similar drugs in Non-Small Cell Lung Carcinoma were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
17
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02879097 | Phase 3 | UNKNOWN |
Competing Products
20 competing products in Non-Small Cell Lung Carcinoma